Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Escalon MedicalESMC 34 EV-to-EBITDA is -0.11 as of Jul. 22, 2026. GuruFocus rates ESMC with a GF Score™ of 34/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Escalon Medical ranks better than 99.41% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Escalon Medical's enterprise value is $-0.20 Mil.
Escalon Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1.90 Mil. Therefore, Escalon Medical's EV-to-EBITDA for today is -0.11.
The historical rank and industry rank for Escalon Medical's EV-to-EBITDA or its related term are showing as below:
ESMC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.59 Med: -0.67 Max: 179.59
Current: -0.11
During the past 13 years, the highest EV-to-EBITDA of Escalon Medical was 179.59. The lowest was -41.59. And the median was -0.67.
ESMC's EV-to-EBITDA is ranked better than 99.41% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 13.93
vs ESMC: -0.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Escalon Medical (OTCPK:ESMC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Escalon Medical's PE Ratio (TTM) for today is calculated as:
Escalon Medical's share price for today is $0.20.
Escalon Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.110.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Escalon Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Escalon Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Escalon Medical EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Escalon Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Escalon Medical's EV-to-EBITDA falls into.
Escalon Medical's current Enterprise Value is $-0.20 Mil.
Escalon Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Escalon Medical (ESMC) has a EV-to-EBITDA of -0.11 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Escalon Medical. According to the industry distribution chart, Escalon Medical ranks #3 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 0.59999999999999%.
Is Escalon Medical's EV-to-EBITDA too high?
Escalon Medical's current EV-to-EBITDA is -0.11. Based on the distribution chart, Escalon Medical ranks #3 out of 510 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Escalon Medical has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Escalon Medical's EV-to-EBITDA compare to RBOT and NUWE?
According to the Medical Devices & Instruments industry distribution chart, Escalon Medical ranks #3 out of 510 companies for EV-to-EBITDA. This places Escalon Medical in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.93, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Escalon Medical. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Escalon Medical's current EV-to-EBITDA is -0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Escalon Medical stock overvalued right now?
Based on GuruFocus' analysis, Escalon Medical (ESMC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.20 — trading 33.3% above its estimated fair value. The current EV-to-EBITDA is -0.11. Escalon Medical's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Escalon Medical (ESMC), the current EV-to-EBITDA is -0.11 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Escalon Medical (ESMC) Overvalued in 2026?
Based on GuruFocus' analysis, Escalon Medical stock appears to be overvalued.
The current stock price of $0.20 is trading 33.3% above its estimated GF Value™ of $0.15.
GuruFocus considers Escalon Medical to be Significantly Overvalued.
Key valuation signals for ESMC:
EV-to-EBITDA: -0.11
GF Value™: $0.15 vs. price of $0.20 (33.3% above fair value)
No single metric tells the full story. See the ESMC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Escalon Medical Corp operates in the healthcare market, specializing in the development, manufacture, marketing, and distribution of medical devices and pharmaceuticals in the area of ophthalmology. Its products are A-Scans, B-Scans, UBM, Pachymeters, Ispan Intraocular Gases, Surgical Packs, Viscous Fluid Transfer Systems, and AXIS Image Management. Substantial revenue is generated from the domestic sales of products.
34GF Score
Get the complete analysis for ESMC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESMC has been successfully added to your 
